In ER+ breast cancer, GCs exert tumor-suppressive effects through GR-ER signaling crosstalk (5): Mechanistic studies reveal that Dex not only directly inhibits ER transcriptional activity to block tumor proliferation (6), but also epigenetically silences metastasis-promoting pathways, such as the miR-708-mediated RhoA/integrin axis (7). Here, ESR1 is linked to breast cancer.